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TDP-43 cleavageAccumulation of transactive response DNA binding protein (TDP-43) fragments in motor neurons is a post
mortem hallmark of different neurodegenerative diseases. TDP-43 fragments are the products of the apoptotic
caspases-3 and -7. Either excessive or insufﬁcient cellular Ca2+ availability is associated with activation of apo-
ptotic caspases. However, as far as we know, it is not described whether activation of caspases, due to restricted
intracellular Ca2+, affects TDP-43 cleavage. Here we show that in various cell lineageswith restricted Ca2+ avail-
ability, TDP-43 is initially cleaved by caspases-3 and -7 and then, also by caspases-6 and -8 once activated by
caspase-3. Furthermore, we disclose the existence of a TDP-43 caspase-mediated fragment of 15 kDa, in addition
to the well-known fragments of 35 and 25 kDa. Interestingly, with respect to the other two fragments this novel
fragment is themajor product of caspase activity onmurine TDP-43whereas in human cell lines the opposite oc-
curs. This outcome should be considered when murine models are used to investigate TDP-43 proteinopathies.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Intracellular Ca2+ homeostasis regulates several cellular functions,
including metabolism, proliferation and differentiation [1]. It is tightly
controlled by Ca2+ supplementation from intracellular stores, such as
ER, as well as from the extracellular environment, through stimuli act-
ing on voltage- or receptor-operated channels on the plasmamembrane
in different cell types. In neuronal cells synaptic plasticity and release of-AM, 1,2-bis (o-aminophenoxy)
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audo).
ights reserved.neurotransmitters are monitored by Ca2+ [2,3]. In fact, alterations of
intracellular Ca2+ homeostasis are behind several neurodegenerative
diseases including Alzheimer's disease [4–6], Parkinson's disease [7],
multiple sclerosis [8], Huntington's disease [9], epilepsy [10], bipolar
disorder and schizophrenia [4]. Ca2+ homeostasis is also altered in
ALS, in which the excitotoxic process consists in excessive Ca2+ intake
by motor neurons due to overactivation of ionotropic glutamate recep-
tors [11]. An overload of Ca2+ is referred to contribute to necrotic or
apoptotic cell death through mitochondrial dysfunctions, aberrant pro-
duction of ROS, and ER stress [12–14]. However, emerging evidence
suggests that also restricted cellular Ca2+ availability triggers apoptosis
in multiple cell types. In particular, cells incubated with extracellular
[15–17] as well as intracellular [18] Ca2+ chelators undergo cell death
mediated by activation of caspase-3, known to behave as an executor
of the apoptotic process.
TDP-43 is a protein of about 45 kDa, ubiquitously expressed. It is
prominently localized in the nucleus, where it facilitates RNA splicing
and transcriptional repression, and minimally in the cytoplasm al-
though it shuttles back and forth between these compartments [19].
However, its precise function is not fully characterized. One of the path-
ological hallmarks of ALS and FTLD is TDP-43 sequestered inside neural
inclusions in its native form as well as in abnormal forms, particularly
C-terminal fragments [20–22]. The aggregation of the latter species
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attempted to understand the origin and properties of these TDP-43
truncated species to elucidate the pathogenic mechanisms characteriz-
ing the two diseases. These fragments are described to be the products
of the proteolytic activity of apoptotic caspases [25–32]. In detail, TDP-
43 cleavage by caspases-3 and -7 culminates in the generation of
three species of approximately 42, 35, and 25 kDa, of which the latter
two accumulate in neural inclusions of ALS and FTLD cases [23,33].
Recent reports associate these fragments also with Alzheimer's and
Parkinson's diseases [30,31].
Activation of apoptotic caspases can be triggered by a wide range of
extracellular or intracellular signals. An understanding of these signals
should help explain the role of TDP-43 in physiological and pathological
conditions. In FTLD, suppression of progranulin expression has been
associatedwith accumulation of TDP-43 in truncated forms [25], where-
as in experimental conditions these forms are caused by ER stress [32].
However, production of TDP-43 fragments has also been ascribed to
calpains [34], another group of proteases involved in cell death, which
are strictly dependent on Ca2+ for their activity.
Since apoptotic caspases are activated by reduced cellular Ca2+
availability (see above), in this study we assess if decreased cell Ca2+
availability is associated with TDP-43 fragmentation and, were this the
case, which caspases are involved. To this aim TDP-43 fragmentation
was evaluated in cells exposed to EDTA or BAPTA-AM which are extra-
cellular and intracellular Ca2+ respectively. Furthermore, sinceNi2+ and
Co2+ enhance cell apoptosis through different mechanisms [35] but
only Ni2+ blocks Ca2+ channels in neuronal and non-neuronal cells
[17,36–39], thereby mimicking the effect of extracellular Ca2+
chelators, TDP-43 fragmentation was evaluated in cell lines exposed to
the two cations.
2. Materials and methods
2.1. Reagents
TDP-43 monoclonal antibody clone 2E2-D3 (H00023435-M01)
and TDP-43C-terminal (PAB12006) antibodies were purchased from
Abnova (Taipei, Taiwan). TDP-43 polyclonal antibody (10782-2-AP)
and human full-length TDP-43 6*His fusion protein (ag13119) were
purchased from ProteinTech (Chicago, IL, USA). His-probe antibody
(sc-8036), caspase-6 (sc-15381), caspase-8 (sc-7890), β-tubulin
(sc-9104) antibodies and secondary antibodies conjugated to HRP
were obtained from Santa Cruz Biotechnology (Heidelberg, Germany).
Polyclonal antibodies against caspases-3, -7, and -9, as well as against
PARP were included in a kit (#9915) purchased from Cell Signaling
Technology. The active human recombinant caspase set IV (K233-10-
25) was purchased from BioVision (Milpitas, CA, USA). Oregon Green®
488 BAPTA-1, AM (06807) was purchased from (Life Technologies,
Monza, Italy). Protein molecular markers (SM0671) were purchased
from Fermentas. PVDF membranes and the LuminataTM Forte Western
HRP Substrate were purchased from Millipore (Milan, Italy). Nitrocellu-
lose membranes (RPN303D) were purchased from Amersham (Milan,
Italy). Lymphoprep® (1114545) was purchased from Axis-Shield (Oslo,
Norway). The RC DC Protein Assay Kit (500-0119) was purchased from
Bio-Rad (Milan, Italy). High grade versions of all other chemicals used
in this study were purchased from Sigma-Aldrich (Milan, Italy).
2.2. Caspase cleavage of TDP-43 in vitro
Recombinant human full-length 6*His-tagged TDP-43 protein (2 μg)
was separately incubated with 2 U of each active human caspase
(caspases-1, -2, -3, -4, -5, -6, -7, -8, -9, and -10) for 180 min at 37 °C in
the reaction solution recommended by the manufacturer (50 mM
HEPES pH 7.2, 50 mM NaCl, 0.1% CHAPS, 10 mM EDTA, 5% glycerol,
and 10mMDTT) or in the preferred reaction conditions for each caspase
[40]. The cleavage reaction was terminated by the addition of 2×Laemmli loading buffer; samples were boiled and then kept stored at
−20 °C.
2.3. Cell culture and treatments
Freshly isolated circulating lymphomonocytes were collected in
heparin-coated tubes as previously described [41] and then incubated
in RPMI 1640 supplemented with 10% FBS and an antibiotic cocktail
(1×) at 37 °C and 5% CO2. Human acute monocytic leukemia (THP-1)
suspension cell line was incubated in RPMI 1640 supplemented with
10% FBS and an antibiotic cocktail (1×) at 37 °C and 5% CO2. Human car-
cinoma of the uterine cervix (HeLa), human glioblastoma (U87-MG),
and human neuroblastoma (SJ-N-KP) adhesion cell lines were incubat-
ed in high glucose DMEM supplementedwith 10% FBS and an antibiotic
cocktail (1×) at 37 °C and 5% CO2. Astrocytes were isolated from brain
cortices of postnatal day 1–3 mice, as previously described [42,43],
and cultured in high glucose DMEM supplemented with 10% FBS and
an antibiotic cocktail (1×) at 37 °C and 5% CO2. Mice C57BL/6N strain
was bred according to the NIH guide for the Care and Use of Laboratory
Animals. Mice were sacriﬁced with carbon monoxide (CO2).
Adhesion cell lines grown to ~80% conﬂuence or 5 × 105 cells in sus-
pension were treated with the extracellular divalent cation chelator
EDTA (4 or 5 mM), the highly selective cell-permeable Ca2+ chelator
BAPTA-AM (50 μM), NiCl2 (1 mM), or CoCl2 (1 mM) for different
times. For immunoblotting experiments, cells were washed with PBS,
lysed in a buffer consisting of 50 mM Tris pH 6.8, 5% (w/v) SDS, 4 M
deionized urea, and 2% (v/v) 2-mercaptoethanol, aliquoted and then
frozen at−70 °C.
2.4. Western immunoblot analysis
Frozen sampleswere subjected to SDS-PAGE using 12% gels as previ-
ously described [41]. Resolved proteins were then electro-transferred
overnight onto PVDF or nitrocellulose membranes in a transfer buffer
containing 48 mM Tris, 39 mM glycine, 20% (v/v) methanol, and 0.04%
(w/v) SDS (pH 9.2) at 4 °C. Membranes were blocked with 2% BSA in
TBST buffer consisting of 0.02 M Tris–HCl pH 7.6, 0.14 M NaCl, and
0.02% (v/v) Tween 20. Membranes were then exposed to different anti-
bodies in 5% BSA in TBST buffer. Next, membranes were washed with
TBST buffer, incubated with 15 ng/ml of appropriate HRP-conjugated
secondary antibodies at 4 °C, washed again and then exposed to the
enhanced chemiluminescence HRP substrate. The immunostained
bands were visualized using a Chemi-Box CCD gel imaging system and
Genesnap image acquisition software (Syngene, UK).
To further assess the proteolytic TDP-43 bands, a slice of the SDS-
PAGE gel, that contained the His-tagged TDP-43 protein (Mr about
50 kDa), was dissected and then incubated overnight at 37 °C in an
extraction buffer containing 50 mM Tris–HCl, pH 7.9, 0.15 M NaCl,
0.1% SDS, 0.1 mM EDTA, and 5 mM DTT. The sample was then centri-
fuged to remove polyacrylamide gel residues. To concentrate the
recombinant TDP-43 amount in the sample, four volumes of cold acidi-
ﬁed acetone/methanol (1:1) were added to one volume of the protein
extract. This mixture was kept overnight at−20 °C, and then centri-
fuged at 14,000 g at 4 °C for 15 min. The subsequent supernatant was
discarded and the pellet was dried in a vacuum. Finally, the pellet was
resuspended in the caspase reaction solution recommended by the
manufacturer, incubated with 2 U of caspase-8, subjected in vitro to
the caspase cleavage assay described above, and then to SDS-PAGE.
2.5. Mass spectrometry
Coomassie G-stained bands were excised from the SDS-PAGE gels;
destaining and in-gel enzymatic digestionwere performed as previously
described [44]. Brieﬂy, each bandwasdestainedwith 50%v/v acetonitrile
in 5mMammoniumbicarbonate, driedwith acetonitrile and rehydrated
for 45 min at 4 °C in 10 μl of a digestion buffer containing 5 mM
Table 1
Caspases involved in the proteolysis of TDP-43.a
Caspase- TDP-43 proteolysis
Apoptotic caspases
2 − (pH 7.2)
+ (pH 6.5)
3 +
6 +++
7 ++
8 ++
9 −
10 −
Inﬂammatory caspases
1 −
4 −
5 −
a The ability of caspases of cleaving TDP-43 was evaluated
based on the immunoreactive intensity of the full length
TDP-43 and the 35 kDa, 25 kDa and 15 kDa truncated species.
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to proceed overnight at 37 °C and the peptide mixtures were stored at
4 °C until assayed. The digests were analyzed by a MALDI-TOF system
(TofSpec SE, MicroMass) equipped with a delayed extraction unit. Prior
to MALDI-TOF analysis, each peptide mixture was mixed with an equiv-
alent volume of a saturated solution ofα-cyano-4-hydroxycinnamic acid
in 40% v/v acetonitrile–0.1% v/v triﬂuoroacetic acid. The MALDI-TOF sys-
temwas calibrated with a polyethylene glycol mixture (PEG 1000, 2000,
and 3000 in the ratio 1:2:2) and mass spectra were acquired in the
positive-ion mode. Peak lists were generated with ProteinLynx Data
Preparation (ProteinLynx Global Server 2.2.5) using the following
parameters: external calibration with a lock mass = 2465.1989 Da of
adrenocorticotropic hormone background subtract type adaptive com-
bining all scans, performing deisotoping with a threshold of 1%.
Peak lists were used for ProteinLynx Global Server 2.2.5 search using
a database containing human TDP-43. The search settings allowed
one missed cleavage with the trypsin enzyme selected, oxidation of
methionine as a potential variable modiﬁcation, a peptide tolerance of
100 ppm.
2.6. Evaluation of intracellular Ca2+ levels
HeLa or SJ-N-KP cells, suspended in the indicated culture medium
(Section 2.3), were seeded in 96-well tissue culture plates at a density
of 15,000 cells per well and kept under 5% CO2 at 37 °C overnight.
Cells were exposed or not to 5 mM EDTA, or 50 μM BAPTA-AM, or
1 mM NiCl2, and after 30 min, loaded with Oregon Green® 488
BAPTA-1, AM (2.5 μM ﬁnal concentration). Fluorescence intensity was
monitored for 5 h at 10 minute intervals at 37 °C, using Fluoroskan
Ascent Microplate Fluorometer (Thermo-Labsystems) set at 485 nm
excitation wavelength and 538 nm emission wavelength. BackgroundFig. 1. Caspases involved in the cleavage of TDP-43 in vitro. Western immunoblot analysis
of recombinant human full-length 6*His-tagged TDP-43 protein (2 μg) separately incubat-
ed with 2 U of each recombinant active human caspases-1, -2, -3, -4, -5, -6, -7, -8, -9, and
10, in the reaction buffer according to the manufacturer's instructions, and revealed with
TDP-43 A) monoclonal, B) polyclonal and C) C-terminal antibodies; D) incubation of the
recombinant TDP-43 with active caspase-2 in the abovementioned buffer (M) compared
with the optimal buffer (Opt) [40]. Comparable results were obtained in two other inde-
pendent experiments. *35 kDa proteolytic product. **25 kDa proteolytic product.
***15 kDa proteolytic product.ﬂuorescence control consisted in culture medium supplemented with
vehicles (deionized water for EDTA, NiCl2, and CoCl2, or DMSO for
BAPTA-AM).
3. Results
3.1. Caspase-mediated cleavage of TDP-43 in vitro
To assess which caspases are involved in TDP-43 fragmentation, full-
length human recombinant TDP-43 with a 6*His tag at the N-terminus
was incubated with a broad spectrum of caspases in the assay condi-
tions suggested by the manufacturer. Western immunoblot analysis
demonstrated that TDP-43 is cleaved by caspases-3 and -7 (Fig. 1,
Table 1), as previously reported, and by caspase-8, instead referred to
be unsuccessful [25]. As a novelty, TDP-43 was seen to be a substrate
also of caspase-6, and minimally of the other caspases (Fig. 1, Table 1).
These results were conﬁrmed using a buffer reported to be optimal
[40] with TDP-43 cleavage referred to caspase-2 now appreciable
(Fig. 1D, Table 1).
To characterize the proteolytic products of TDP-43, blot stainingwas
carried out with a monoclonal antibody (targeting epitopes 205–222
[45]), or a polyclonal antibody (targeting epitopes 203–209 and an un-
known sequence in the N-terminal region [46]), or a C-terminal poly-
clonal antibody (targeting epitopes 350–414), or an anti-His antibody
(targeting the 6*His tag at the N-terminus of the recombinant protein).
Three distinct TDP-43 fragments of approximately 35, 25, and 15 kDaFig. 2. Identiﬁcation of TDP-43 fragments produced by caspases. Western immunoblot
analysis of recombinant human full-length 6*His-tagged TDP-43 isolated from the SDS-
PAGE gel, incubated with recombinant active human caspase-8 and stained with TDP-43
monoclonal, polyclonal, C-terminal antibodies as well as with an antibody against the
N-terminal poly-His sequence. Similar outcomeswere obtained in two other independent
experiments. Blot staining in the lane of recombinant protein not supplemented with
caspase-8 was obtained with the TDP-43 polyclonal antibody and reproduced using the
other antibodies tested. *35 kDa proteolytic product. **25 kDa proteolytic product. ***15
kDa proteolytic product. ****42 kDa proteolytic product.
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by the three TDP-43 antibodies, while the 15 kDa fragment by the poly-
clonal antibody only (Fig. 1). To remove non-speciﬁc bands interfering
with the correct interpretation of the outcomes, the 50 kDa His-taggedFig. 3.MALDI-TOF analysis of caspase-mediated TDP-43 fragments. MALDI-TOF spectra of reco
fragments at 35 kDa, 25 kDa and 15 kDa, referable to blots reported in Fig. 2. The arrows indic
(amino acid sequence 276–293 of human TDP-43, UniProtKB Q13148) included in the C-term
documented caspase cleavage site DVMD219.full-length protein band was excised, extracted from the gel, exposed
to cleavage by caspase-8, and then analyzed with the western blot
procedure (Fig. 2). The TDP-43 cleavage products here observed were
similar to those illustrated in Fig. 1. However, with this procedure ambinant human 6*His-tagged full length TDP-43 and of its caspase-dependent proteolytic
ate the peaks at 1726 m/z corresponding to the tryptic peptide FGGNPGGFGNQGGFGNSR
inal fragments, because it is localized in the TDP-43 amino acid sequence beyond the last
Fig. 5. Time-dependent effects of EDTA, BAPTA-AM, and NiCl2 on intracellular Ca2+ levels,
evaluated in HeLa cells. Cells were incubatedwith 5mMEDTA, 50 μMBAPTA-AMor 1mM
NiCl2. Fluorescence was measured in cells incubated with 2.5 μM Oregon Green® 488
BAPTA-1, AM and reported in arbitrary units. Traces are representative of three indepen-
dent experiments. Values are means ± standard deviations. The signiﬁcance level for p
was set at less than 0.1 (*).
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in Fig. 1, was better deﬁned and targeted by all the three antibodies. This
band was clearly revealed in the presence of caspase-8, barely with
caspase-6 and was almost unappreciable with caspases-3 and -7
(Fig. 1). Furthermore, the anti-His antibody detected only the 50 kDa
band corresponding to the full-length His-tagged TDP-43 (Fig. 2).
Thus, all four proteolytic fragments here identiﬁed lack the N-terminal
region, because the TDP-43 recombinant protein used is His-tagged at
the N-terminus.
MALDI-TOF spectrum of the full-length TDP-43 as well as of the 35
kDa and the 25 kDa fragments were all characterized by a peak at
1726 m/z, corresponding to the TDP-43 276–293 trypsin fragment.
This amino acid sequence is localized beyond the last documented cas-
pase cleavage site DVMD219 (Suppl. Fig. S1), towards the C-terminal re-
gion. The peak corresponding to this peptidewas not detected in the 15
kDa fragment spectrum (Fig. 3). Based on these results, and in agree-
ment with the previous report of Zhang et al. [25], the 42 kDa and 35
kDa proteolytic products must be identiﬁed as the amino acid se-
quences 14–414 and 90–414 of TDP-43, respectively. However, Zhang
et al. identiﬁed the 25 kDa band as the TDP-43 amino acid sequence
220–414. Were this so, this fragment should not have been detected
by the monoclonal antibody, as instead was the case, because cleavage
at Asp219 disrupts the epitope targeted by this antibody [45]. Since ourFig. 4. TDP-43 proﬁle in different cell types treated with EDTA. A)Western immunoblot analysi
astrocytes (m-astro) not exposed or exposed to 4mMEDTA, using the TDP-43 polyclonal antibo
results. B) Bar graphs illustrating, the ratio in each lane between the immunoreactive intensity
was evaluated for each experiment, expressed as arbitrary units and illustrated in the graph as
level for p was set at less than 0.01 (**). C) Western immunoblots from human (MDA-MB-231
exposed to recombinant active human caspase-7 and revealed with the TDP-43 polyclonal ant
for a statistical analysis. *35 kDa proteolytic product. **25 kDa proteolytic product. ***15 kDa poutcomes conﬁrm the presence of the protein C-terminus in this spe-
cies, the 25 kDa band here detected should be the 170–414 fragment
described by Nishimoto et al. [47] and Suzuki et al. [32]. The band ofs of circulating lymphomonocytes (CLM), THP-1, HeLa, U87-MG, SJ-N-KP cells andmurine
dy. The evaluationwas carried out in twoother independent experimentswith comparable
of TDP-43 full-length band and the intensity of TDP-43 cleavage product bands. The ratio
a mean value reported in the three experiments ± standard deviations. The signiﬁcance
), monkey (COS-2), murine (dermal ﬁbroblast) and canine (MDCK) cells not exposed or
ibody. n.d.: the immunostaining of the proteolytic fragment was too low to be considered
roteolytic product.
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pase cleavage. A species with the same Mr has been described as a C-
terminal fragment of TDP-43 [48]. Our results indicate that this product
retains neither theN-terminal nor the C-terminal regions; in addition, it
includes the amino acid sequence 203–209 (the polyclonal antibody
epitope), but lacks at least a part of the amino acid sequence 205–222
(the monoclonal antibody epitope). Based on the caspase cleavage
sites found by the CASVM server [49], the 15 kDa peptide must corre-
spond to the amino acid sequence 90–219 of TDP-43.
3.2. Caspase-mediated TDP-43 cleavage in Ca2+-deprived cells
3.2.1. Extracellular Ca2+ chelation and TDP-43 cleavage in different cell
types
To assess whether reduced Ca2+ availability is associated with
caspase-mediated cleavage of TDP-43, six cell types were exposed to 4
mM EDTA and then subjected to western blot analysis with the TDP-
43 polyclonal antibody (Fig. 2). TDP-43 immunoreactive bands of 35,
25, and 15 kDa were disclosed, and reﬂected those detected in in vitro
experiments (Fig. 1), with the 35 kDa immunoreactive band more
evident than the other two. In detail, in THP-1, HeLa, U87-MG, and SJ-
N-KP cells these bands were faintly detectable in basal conditions.
Exposure to EDTA dramatically improved the detection of these bands
in parallel with a decrease of the full-length protein. In circulating
lymphomonocytes the proteolytic species of TDP-43 were not detected
in basal conditions and only minimally once exposed to EDTA (Fig. 4A).
To quantify the generation of proteolytic fragments from TDP-43
full-length, the ratio between the immunoreactive intensity of TDP-43
full-length band vs. intensity of each TDP-43 cleavage product is report-
ed for untreated and treated cells (Fig. 4B).
3.2.2. Caspase-mediated cleavage of human and murine TDP-43
The TDP-43 fragmentation pattern was also a feature of EDTA-
treated primary cultured murine astrocytes, although it differed for
some aspects with respect to that of human cultured cells. In murine
cells the TDP-43 full-length and the 35 kDa fragment were appreciable
in basal conditions. EDTA treatment decreased the intensity not only
of the full length immunoreactive band, but also of the 35 kDa one.
The 25 kDa bandwas not detected, whereas the 15 kDa bandwas signif-
icantly increased (Fig. 4A, C).
The only difference in the TDP-43 sequences targeted by caspases
concerns the consensus site 216–219, which corresponds to the DVMD
amino acid sequence for the human protein, and the EVVD sequence in
the murine protein. This is one of the two consensus sites cleaved by
caspases to generate the 15 kDa fragment (see above).
Human (MDA-MB-231), monkey (COS-1), murine (primary dermal
ﬁbroblasts), and canine (MDCK) cell lysates in the caspase reaction buff-
er previously described (Section 2.2)were incubatedwith 2 U of human
recombinant caspase-7 for 180 min at 37 °C. The cleavage of human
andmonkey TDP-43, both sharing the consensus site DVMD219, resulted
in the generation of the 35 kDa, the 25 kDa and 15 kDa products. The
cleavage of murine and canine TDP-43, both retaining the consensus
site EVVD219, instead resulted in the generation of the 15 kDa product
only (Fig. 4C).
3.2.3. Cytoplasmic Ca2+ levels in cells exposed to EDTA, BAPTA-AM and
NiCl2
Ca2+ levels were evaluated in HeLa as well as SJ-N-KP cells exposed
for different times to EDTA, BAPTA-AM, and NiCl2.Fig. 6. Time-dependent effects of EDTA, BAPTA-AM, NiCl2, and CoCl2 on TDP-43 and PARP clea
analysis of cells treated with 5 mM EDTA, 50 μM BAPTA-AM, 1 mM NiCl2 or 1 mM CoCl2. TDP-
precursors (PROCASP-X) and, where possible, in their active form (CASP-X). β-Tubulin was use
of the immunostained bands of TDP-43 full-length vs. that of 35 kDa in the different treatments
includes the ratio between the intensity of the immunoreactive bands of each procaspase, norm
same times (PROCASP-X).Oregon Green® 488 BAPTA-1-AM was applied, as it is a cell-
permeable indicator that exhibits a ~14-fold increase in ﬂuorescence
upon binding Ca2+. Each point in the graph (Fig. 5) is the measure of
the intensity of ﬂuorescence registered at speciﬁc times, expressed in
arbitrary units.
In HeLa control cells, ﬂuorescence intensity increased linearly,
signaling an increase in the number of cells taking up Ca2+ from the
external environment to preserve cellular functions [1]. In HeLa cells ex-
posed to BAPTA-AM ﬂuorescence remained unvaried and signiﬁcantly
below that of control cells at all the times considered. BAPTA-AM rapidly
sequestrates cytoplasmic Ca2+, either of intra or extracellular origin, in
line with its properties of intracellular Ca2+ chelator.
In cells treated with EDTA ﬂuorescence intensity increased in paral-
lel with that of control cells until approximately 180 min but then
remained unvaried whereas that of controls continued to rise. There-
fore, in cells exposed to EDTA the initial cellular Ca2+ availability is
unaltered, as opposed to what happens in cells exposed to BAPTA-AM.
Thus the effects of Ca2+ sequestration outside the cell can be detected
only when external Ca2+ requirement of an appreciable number of
cells is no longer satisﬁed.
In HeLa cells exposed to NiCl2 ﬂuorescence intensity was compara-
ble to controls (Fig. 5) whereas in similarly treated SJ-N-KP cells, it
was comparable to that in HeLa cells (Suppl. Fig. S2).
3.2.4. Cleavage of TDP-43 and activation of caspases in cells exposed to
EDTA, BAPTA-AM, NiCl2, and CoCl2
Time-related experimentswere performed inHeLa and SJ-N-KP cells
exposed to EDTA, BAPTA-AM, NiCl2 as well as to CoCl2. Using western
immunoblot analysis, TDP-43 cleavage was compared with that of
PARP, a well known caspase substrate. Results were referred to the ac-
tivity of caspases as expressed by the detection of the active forms or,
where impossible to determine, as the decrease of their precursors.
In EDTA-treatedHeLa cells, TDP-43 cleavagewas progressivelymore
appreciable from 6 to 18 h, when the full-length TDP-43 collapsed
almost completely into its proteolytic products of 35, 25 and 15 kDa
(Fig. 6). In these cells exposed to BAPTA-AM, TDP-43 fragments were
appreciable already at 3 h, but degradation of the full-length protein
proceeded slowly with respect to that in EDTA treated cells, with a rel-
atively large amount of constitutive TDP-43 still evident at 24 h. The
trend of PARP cleavage in EDTA or BAPTA-AM treated cells reproduced
that described above for TDP-43 in the respective contexts.
In HeLa cells the proﬁle of activation of caspases-3 and -7 ranparallel
to that of TDP-43 fragmentation. In detail, in EDTA-treated cells intensi-
ty of procaspase-3 blot staining progressively decreased, and was no
longer appreciable after 18 h, as opposed to that of the active forms.
This trend was roughly comparable with the caspase-7 one, although
the active formwas already appreciable after just 9 h,maybe depending
on the greater sensitivity of the antibody used. In BAPTA-AM treated
cells, the progressive decrement of the two procaspases was less prom-
inent than in EDTA-treated cells, although the caspase-7 active
form was detected already after 3 h. The decrement of procaspases-6
and -8 in both EDTA and BAPTA-AM treated cells was less evident if
compared with that of procaspases-3 and -7. Active caspase-8 was de-
tected after 18 h of EDTA and faintly after 24 h of BAPTA-AM treatment.
We failed to detect the active formof caspase-6, although laminA, a typ-
ical substrate of this caspase, was found to be degraded only in the late
treatment stages (Suppl. Fig. S3). Caspase-9was not seen to be involved
in the cleavage of TDP-43; all the same we evaluated its activation pro-
ﬁle in order to better deﬁne the caspase activation hierarchy. Caspase-9vage and on the activation of caspases, evaluated in HeLa cells. A) Western immunoblot
43 fragmentation was revealed with the polyclonal antibody. Caspases were evaluated as
d as a measure of equal protein loading. B) The graph bar illustrates the ratio of intensity
compared to that of untreated cells at the same times (43/35). Additionally, the graph bar
alized with respect to tubulin, in the different treatments vs. that of untreated cells at the
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ments, respectively.
In HeLa cells exposed to NiCl2 or CoCl2 TDP-43 and PARP cleavage
proﬁle, as well as the activation of caspases-3 and -7, were barely
detected up to 9 h, and instead evident after 18 and 24 h. In the same
cells, activation of caspases-6 and -8 occurred later than that of
caspases-3 and -7 (Fig. 6, Suppl. Fig. S3). Activation of caspase-9 was
clearly detected after 18 h as was that of caspases-3 and -7.
In SJ-N-KP cell lineage, the proﬁles of TDP-43 and PARP, as well as
of caspases were similar to the ones in HeLa cells, with only a slightly
delay in cleavage of TDP-43 and PARP and of activation of caspases.
In these cells exposed to NiCl2 and CoCl2 TDP-43 and PARP degradation
was more relevant than what was observed in HeLa cells (Suppl.
Fig. S4).
4. Discussion
Impairment of Ca2+ homeostasis has been described in many
neurodegenerative diseases. In some cases, such as ALS, increased intra-
cellular Ca2+, due to impaired inﬂux, in neurons is associated with cell
death. On the other hand, in neural cell lines a decrement of Ca2+ avail-
ability is accompanied by apoptotic death,mediated by caspases, partic-
ularly caspase-3 [15–18].
TDP-43 cleavage products are a feature of post-mortem specimens
of nervous tissue in ALS and FTLD [20–22], although the relative frag-
ments have been found also in other neurodegenerative disordersFig. 7.Mechanisms and pathways involved in TDP-43 cleavage. TDP-43 cleavage by caspases res
15 kDa (90–219). Caspase-9 is apical caspase of the cascade involved in TDP-43 cleavage, althou
caspase-6, in turn responsible for the activation of caspase-8. Caspases-3, -7, -6, and -8 all cont
due to a restriction of cell Ca2+ availability, consequent to a reduced supply from the external e
c following mitochondrial damage. This damage can be attributed to abnormal increase of intr
neurodegenerativediseases, ALS included. Our results suggest that a decrease of Ca2+mayparad
of calpains responsible for the generation of N-terminal TDP-43 fragments. Calpains are predict
calpains [34].[30,31]. These fragments have been ascribed to the proteolytic activity
of apoptotic caspases [25–32]. Here we explore in various cell lines if
and how caspase activation consequent to cell Ca2+ deprivation affects
TDP-43.
We conﬁrm that caspases-3 and -7 cleave TDP-43, although, differ-
ently from what was reported [25], caspase-7 is more active than
caspase-3. As a novelty, we unveil that caspases-6 and -8 cleave TDP-
43, as well as caspase-2 in particular experimental conditions, whereas
the other caspases of the ten examinedhave no, orminimal, effects. Two
of the four TDP-43 fragments here detected correspond to the already
described ones with amino acid sequences 14–414 and 90–414 [25].
One, of 25 kDa, is likely the fragment 170–414 described by Nishimoto
et al. [47] and Suzuki et al. [32], thus differing from the onewith approx-
imately the sameMr described by Zhang et al. (220–414) [25]. The last
fragment, of 15 kDa, has never been described before and we believe
corresponds to a caspase-mediated double cleavage atAsp89 andAsp219.
Three of the four TDP-43 fragments (90–414, 170–414 and 90–219)
were here found also in cell lineages exposed to EDTA. Surprisingly, in a
murine cell line TDP-43 collapsed into the 15 kDa form without accu-
mulation of the other products seen in human lineages. We found that
accumulation of this TDP-43 fragment characterizing themouse lineage
is a feature of another animal species that also carries the TDP-43 con-
sensus site EVVD219, whereas it is a minor product of another animal
species carrying the human TDP-43 consensus site DVMD219. Presum-
ably, the greater caspase efﬁciency for the EVVD219 site is due to
enhanced enzyme speciﬁcity for this amino acid sequence rather thanults in the generation of at least three fragments: 35 kDa (90–414), 25 kDa (170–414) and
gh unable to cleave TDP-43. Caspase-9 activates caspases-3 and -7, and caspase-3 activates
ribute to the fragmentation of TDP-43. Here we describe activation of this caspase cascade
nvironment. Activation of apoptotic caspases can be also caused by release of cytochrome
acellular Ca2+ and overproduction of ROS, both considered to be at the heart of different
oxically cause an increase of intracellular Ca2+. Excessive Ca2+ inﬂux causes also activation
ed to activate caspases, which in turn degrade the TDP-43 fragments already produced by
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only two amino acid residues in a highly conserved protein [19]
profoundly changes caspase afﬁnity. In this view, only certain animal
species, not including mouse, are suitable for experiments aimed at
establishing the role of TDP-43 fragments in the onset of TDP-43
proteinopathies.
Fluorescence analysis of Ca2+ was performed in two cell lineages
(HeLa and SJ-N-KP). In both cell types treated with BAPTA-AM, Ca2+
availability drops after 1 h (Fig. 5). In the same cells treated with
EDTA, Ca2+ availability rises, as in controls, up to 3 h, but from then
on, it remains unvaried, i.e. well below control cells and well above
BAPTA-AM treated cells. These differences should be ascribed to the
fact that BAPTA-AM is an intracellular, whereas EDTA an extracellular,
Ca2+chelator. In particular, with EDTA, Ca2+ availability takes longer
to drop because, differently from the case of BAPTA-AM, intracellular
Ca2+ remains available.
As said above, in different cell lineages treated with EDTA, TDP-43
fragments overlapped those detected in in vitro experiments. Thus, re-
striction of extracellular Ca2+ supply and cleavage of TDP-43 mediated
by caspases appear to be related. In HeLa and SJ-N-KP cell lines treated
with either EDTA or BAPTA-AM, TDP-43 cleavage runs parallel with
that of PARP, a typical caspase substrate. Cleavage occurs later in cells
treated with EDTA with respect to BAPTA-AM. In both EDTA and
BAPTA-AM treatments, TDP-43 and PARP fragmentation begins once
caspases-3 and -7 are activated, and here too, their activation occurs
earlier in cells treated with BAPTA-AM, than in those treated with
EDTA. Furthermore, caspase-6 is activated by caspase-3 and in turn ac-
tivates caspase-8, and both contribute to TDP-43 cleavage. Caspase-9,
that failed to cleave TDP-43, is also activated in the early stages of treat-
ment, in parallel with caspases-3 and -7. Thus, caspase-9 is the apical
caspase of the cascade involved inTDP-43 cleavage with EDTA and
BAPTA-AM treatments. The cascade of caspase activation here reported
is in line with the hierarchical order of the activation of caspases
described in other reports [50,51]. Therefore, TDP-43 cleavagemediated
by apoptotic caspases is associatedwith decreased cell Ca2+ availability.
TDP-43 cleavage and the same caspase cascade activation typifying
EDTA and BAPTA-AM treatments are also a feature of cells exposed
to Ni2+ and Co2+. Ni2+ does not affect Ca2+ availability at the various
times (Fig. 6), although described to be a Ca2+ channel blocker
[17,36–39]. Thus, its effects on TDP-43 cleavage must not be due to
decreased Ca2+ availability, but rather to some othermechanism, possi-
bly closer to that of Co2+ (which to our knowledge does not affect Ca2+
homeostasis). In this respect, Ni2+ and Co2+ induce activation of
caspases through oxidative stress and mitochondrial dysfunctions
[35]. These two events are hypothesized to be at the heart of different
neurodegenerative diseases, including ALS [52–57].
A fall of extracellular Ca2+, as well as sequestration of free cytosolic
Ca2+, over time cause depletion of intracellular Ca2+ stores, ER included
[18,58,59]. Interestingly, ER stress has been recently reported to be asso-
ciated with TDP-43 cleavage by caspase-3 [32]. Ca2+ delivered from
internal storages counters Ca2+ depletion although at the price of
promoting mitochondrial damage and consequent caspase-mediated
apoptosis [60]. Exposure to EDTA is associated with more severe apo-
ptosis than what occurs with BAPTA-AM, presumably because, differ-
ently from BAPTA-AM, EDTA does not affect Ca2+ delivered from
internal storages. In fact, BAPTA-AM promptly sequesters Ca2+ released
from storages,whereas EDTA cannot. Thus, with BAPTA-AMapoptosis is
only due to diminished Ca2+ availabilitywithout the additional apopto-
tic effect of Ca2+ from internal storages. With EDTA, apoptosis occurs
later than with BAPTA-AM (see above) but is more severe because the
apoptotic effect of released Ca2+ from internal storages is summed to
that of reduced Ca2+ availability. In this regard, BAPTA-AM is reported
to have a protective role when depletion of Ca2+ from ER becomes
toxic for the cell [60–63]. Thus, caspase-mediated cleavage of TDP-43
here described in conditions of reduced Ca2+ availability may also
occur, paradoxically, with high levels of cytoplasmic Ca2+ (Fig. 7).The results of this study suggest that itmay be useful to investigate if
diseases relying on accumulation of TDP-43 fragments are associated
with alterations of intracellular Ca2+ homeostasis and vice versa.
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